We think Coloplast's urology segment could offer growth potential and cross-selling opportunities. Thus far, the firm has been more successful in the United States with its slings, kidney stone ...
Coloplast is now rated a cautious 'Buy,' as its valuation has become more reasonable after a significant price correction. Coloplast continues to deliver solid organic growth, boasts a wide economic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback